Alaunos Therapeutics Inc (TCRT) FinancialsTCRTAlaunos Therapeutics Inc

Evaluating the bottom line, Alaunos Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -185.95%, provide a clear picture of how effectively TCRT converts its operational activities into shareholder value.

In the context of the broader market, TCRT competes directly with industry leaders such as XCUR and CALC. With a market capitalization of $6.68M, it holds a significant position in the sector. When comparing efficiency, TCRT's gross margin of N/A stands against XCUR's N/A and CALC's N/A. Such benchmarking helps identify whether Alaunos Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company's gross margin is currently at 100% for the last reported quarters, indicating strong revenue potential despite recent losses. However, the forward P/E ratio stands at 18.48, reflecting expectations of future profitability.